A phase 2 trial evaluated the effectiveness and safety of neoadjuvant intravesical mitomycin-C instillation in patients with urothelial non-muscle invasive bladder cancer.
Ractigen Therapeutics, a pioneering clinical-stage biotechnology company developing innovative small activating RNA (saRNA) therapeutics, today announced that China's National Medical Products ...
“Identifying individuals at high risk for UTIs allows for more targeted treatment and care strategies, thereby enhancing patient safety.” — Yunlan Jiang, Chengdu University of Traditional Chinese ...
The phase 2, single-arm INDIBLADE trial assessed induction ipilimumab plus nivolumab followed by CRT in patients with MIBC.
Bipolar transurethral resection represents a significant evolution in the surgical management of bladder cancer, particularly for non‐muscle invasive bladder cancer (NMIBC). This technique utilises an ...
Zacks Investment Research on MSN
JNJ's bladder cancer therapy meets key goal in early-stage study
Johnson & Johnson JNJ reported positive results from an early-stage study evaluating its investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with ...
Clinical performance of Bladder EpiCheck methylation test for active surveillance of non-muscle invasive bladder cancer: Systematic review and meta-analysis. This is an ASCO Meeting Abstract from the ...
Physical and Emotional Health Effects and Social Consequences After Participation in a Low-Fat, High-Carbohydrate Dietary Trial for More Than 5 Years For high-risk T1 bladder cancer, the most ...
A person may need surgery for bladder cancer to remove the tumor. A person may also need preoperative or postoperative treatments. Bladder cancer occurs when cells of the bladder start to grow out of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results